Metagenomi Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
7.6%projected annual EPS growth
Analyst Coverage
3analysts covering
FY EPS (est.)
-$2.50next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 10 Nov 2026 |
| Q4 2026 / Full Year 2026 Earnings Release | 4 Mar 2027 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Marketable Securities Quarterly140.2MTarget: Sufficient to fund operations through Q4 2027
Collaboration Revenue Quarterly1.3MTarget: Variable based on Ionis and Affini-T milestones
Quarterly Net Loss Quarterly-23.1MTarget: Controlled burn rate under restructured cost base
Watch Items
- MGX-001 IND SubmissionTrigger: Submission by Q4 2026Action: Monitor SEC filings and press releases for regulatory filing confirmation.
- First-in-Human Clinical Trials for MGX-001Trigger: Initiation in 2027Action: Track clinical trial registry updates and company announcements for patient enrollment.
- Cash Runway and Burn RateTrigger: Runway dropping below 12 monthsAction: Evaluate potential dilutive equity offerings or non-dilutive partnership opportunities.
Research as of 19 Jun 2026